RIBOMIC, Inc. has announced that the first patient has received injection in the phase 2 trial of RBM-007 for the treatment of exudative age-related macular degeneration (AMD) in the United States. The first site started enrollment at the end of December 2019 and five sites are now active across the United States. Currently approved therapies [Read More]
News
“How long will my anti-VEGF drug therapy be effective?”
This is becoming a common question among people who have been treated for years with anti-VEGF drug therapy. These eye injections are the gold standard for treatment of wet age-related macular degeneration (wAMD), having been first used clinically in 2004. The news is good. A recent retrospective review in the U.K. has found that almost [Read More]
New discovery may lead to AMD treatment
Researchers have discovered a protein that might be related to the cause of age-related macular degeneration (AMD) and thus provide insight into early diagnosis and treatment. The study, published in Nature Communications, was a collaboration of Queen Mary University of London, the University of Manchester, Cardiff University, and Radboud University Medical Center, Nijmegen. High levels [Read More]
Smoking Is At An All-Time Low
For over two decades, eye health organizations have worked diligently to increase awareness of the high risks of macular degeneration from tobacco smoking. Now, the recently-released 2020 Surgeon General’s report has revealed that the work of those organizations is paying off. Americans are doing better at making good choices when it comes to smoking. According [Read More]
The T.A.S.K. Of Living With Central Vision Loss
A presentation to the International Low Vision Support Group May 11, 2006 By Dan Roberts, Founding Director Macular Degeneration Support The retina is the thin lining in the back of the eye, and the macula is at the very center. When the macula is healthy, we are able to see in fine detail. When it [Read More]